End Stage Renal Disease patients to whom kidney transplantation is planned
Conditions
Interventions
Standard group Target tacrolimus AUC 0-24 hr 1) til 1 month after transplant 250ng x hr/ml 2) 1 month - 3 months after transplant 200-250 ng x hr/ml 3) 3 months thereafter transplant
Sponsors
Department of Transplant Surgery Kidney Disease Center Nagoya Daini Red Cross Hospital
Kumamoto Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) ABO compatible or mismatch kideny transplant recipient. 2) de novo kidney transplant recipient from non-HLA identical living renal donor. 3) Recipient who can be resposible for the written consents. 4) Women who is no pregnent.
Exclusion criteria
Exclusion criteria: 1) Multiple organ recipient or previous transplant history. 2) HLA identical living related donor. 3) ABO incompatible or T cell CDC-crossmatch positive case. 4) HIV, HCV, HBsAb positive recipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biopsy-proven acute allograft rejection rate after 6 months and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Patient survival rate, Allograft survival rate 2) Incidence of viral infection 3)Incidence rate of de novo donor specific antibody production. | — |
Countries
Japan
Contacts
Public ContactYoshihiko Watarai
Nagoya Daini Red Cross Hospital Transplant Surgery
Outcome results
None listed